Bajaj Healthcare begins production of Nimesulide API

Published On 2021-09-03 05:30 GMT   |   Update On 2021-09-03 12:47 GMT
Advertisement

Thane: Bajaj Healthcare Limited (BHL) a manufacturer of APIs, Intermediates and Formulations, has announced that the company has started commercial production of Nimesulide API at Plot No. N-92, MIDC, Tarapur.

"Nimesulide API" used for relief from pain and prevention of fever. BHL has received approval from FDA Maharashtra (India), to manufacture and market "Nimesulide API" as approved medication for pain relief and prevention of fever in India.

Advertisement
In FY21, the Company has acquired stressed assets from the Saraswat Cooperative Bank under SARFAESI Act, 2002, which comprises of three manufacturing units and one engineering unit at MIDC, Tarapur and having installed capacity of 111 MT per month. BHL has received an approval to start its commercial production in one of the manufacturing unit acquired under SARFAESI Act, 2002 at Plot No. N-92, MIDC, Tarapur.
Commenting on the "commencement of commercial production at Plot no. N 92, MIDC, Tarapur ", Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said "We are pleased to start of commercial production at one of the manufacturing unit acquired under SARFAESI Act, 2002 from Saraswat Bank i.e. at Plot no. N 92, MIDC, Tarapur. This manufacturing unit has Installed Capacity of 40 MT/ p.m. BHL will start commercial production of Nimesulide API from 3rd September, 2021 onwards at Plot no. N 92, MIDC, Tarapur.
FDA Maharashtra (India), has granted permission to manufacture and sales the "Nimesulide API" in the domestic as well as in overseas market.

Read also: Bajaj Healthcare launches black fungus drug Posaconazole API for COVID patients

Bajaj Healthcare Limited a leading manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of of Amino Acids, Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which 6 units are dedicated to APIs, 2 units to Intermediates and 1 unit for formulation.



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News